1. Shah R, Hunt J, Webb TL, Thompson AR. Starting to develop self-help for social anxiety associated with vitiligo: using clinical significance to measure the potential effectiveness of enhanced psychological self-help. Br J Dermatol. 2014;171(2):332-7. [
DOI:10.1111/bjd.12990]
2. Saeedinezhad F, Firouzkouhi M, Abdollahimohammad A, Rahnama M. The challenges facing with vitiligo: a phenomenological research. Int. J. Pharm. Res. Allied Sci., 2016, 5(3):356-364.
3. Aghaei S, Amiri M, Aghaei M, Nilforoushzadeh MA. Molecular genetics and epidemiology of vitiligo: a minireview. Int J Epidemiol Res. 2018;5(3):103-106. [
DOI:10.15171/ijer.2018.22]
4. 4 .Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956-8. [
DOI:10.1111/ijd.12148]
5. Saeedinezhad F, Firouzkouhi M, Abdollahimohammad A and Rahnama M , Aziz Shahrakivahed A (2017).The Lived Experiences of Persons with Vitiligo: A Phenomenological Research. JAMMR, 2017 23(9): 1-8.
6. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31(3):309-18. [
DOI:10.1111/pde.12226]
7. Cupertino F, Niemeyer-Corbellini JP, Ramos-E-Silva M. Psychosocial effects of vitiligo. Clin Dermatol. 2017;35(3):292-297. [
DOI:10.1016/j.clindermatol.2017.01.001]
8. 8 .Spritz R, Andersen G. Genetics of Vitiligo. Dermatol Clin. 2017; 35(2): 245–255. [
DOI:10.1016/j.det.2016.11.013]
9. Dicle O. Assessment Methods in Vitiligo. Pigmentary Disorders 2015; 2: 160.
10. Salah Eldin MM, Sami NA, Aly DG, Hanafy NS. Comparison Between (311-312 nm) Narrow Band Ultraviolet-B Phototherapy and (308 nm) Monochromatic Excimer Light Phototherapy in Treatment of Vitiligo: A Histopathological Study. J Lasers Med Sci. 2017; 8(3):123-127. [
DOI:10.15171/jlms.2017.22]
11. Ahn Wee MD. A case report of extensive vitiligo. Hawaii Tien- Medical Journal. 1997; 56: 37-42.
12. Pacifico A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed. 2011; 27(5):261-77. [
DOI:10.1111/j.1600-0781.2011.00606.x]
13. Singh WG, Gomez AC, Swamy SC, Ashok DN, and Reddy MJ. Approach to a case of vitiligo. Ind J Aerospace Med. 2009; 53(1): 62-65.
14. Manolache L, Petrescu-Seceleanu D. Stress involvement as trigger factor in different skin conditions. World J Dermatol. 2013; 2(3): 16-26. [
DOI:10.5314/wjd.v2.i3.16]
15. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993;32(10):753-7. [
DOI:10.1111/j.1365-4362.1993.tb02754.x]
16. Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology. 1995;190(3):251-2. [
DOI:10.1159/000246705]
17. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, Seok JH, Lee JH, Hur GM. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology. 2000;47(1):35-44. [
DOI:10.1016/S0162-3109(99)00185-X]
18. Singh H, Kumaran MS, Bains A, Parsad D. A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology. 2015;231(3):286-90. [
DOI:10.1159/000433424]
19. Silvan M. The psychological aspects of vitiligo. Cutis 2004; 163-167.
20. Papadopoulos L, Bor R, Legg C, Hawk JL. Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol 1998; 23: 243-248. [
DOI:10.1046/j.1365-2230.1998.00384.x]